Roche is upping its game for the blockbuster ophthalmic drug Vabysmo (faricimab) in a bid to seize more market share from established contenders in Asia, especially China, where the novel therapy is a latecomer.
On 28 November, the Swiss major announced Vabysmo’s listing in China’s National Reimbursement Drug List (NRDL), which will provide the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?